Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.
Aspen announces local availability of Lilly’s Mounjaro

Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.
Aspen and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly diabetes, in recognition of World Diabetes Day.
Aspen has contributed towards the funding of a new mobile cancer screening clinic for rural and peri-urban disadvantaged communities.